Introduction
Despite advances in early detection, better understanding of prostatic anatomy with subsequent re®nement of surgical technique, and improvements in hormonal deprivation therapy, the ability to cure many patients with prostate cancer remains elusive. Nearly a third of newly diagnosed patients already have locally advanced or metastatic disease and patients with advanced, recurrent or metastatic prostate cancer have limited treatment options, all of which lack curative potential.
Androgen deprivation therapy forms the basis of endocrine therapy for the majority of patients with advanced cancer. Androgen ablation offers temporary palliation but all patients eventually progress to hormone refractory disease. This progression occurs eventually for all patients during the course of both conventional and intermittent hormonal ablation, leading to death within 18 months with no real alleviation with current second and third line chemotherapeutic regimens. As they progress to become more malignant, androgen-independent (AI) cells develop resistance to many apoptotic programs induced by various stimuli. The mechanisms of progression of prostate cancer (CaP) cells to hormone independence under androgen ablation therapy remain unclear, however the failure of hormonal ablation to eliminate the entire malignant cell population remains a major obstacle to controlling CaP progression.
Whether cancer progression to an AI stage involves an adaptive mechanism to the androgen withdrawal or selective outgrowth of pre-existing androgen independent clones remains to be established. In either case, it appears that AI variants acquire alternative growth mechanisms during androgen deprivation that permit this adaptive survival. New approaches to delay time to AI progression are therefore needed. Intermittent androgen deprivation (IAD) therapy has recently been proposed as an alternative to continuous androgen blockade, and clinical trials are currently ongoing to evaluate time to tumor progression, safety and quality of life measurements of IAD therapy as compared to continuous androgen blockade. 1, 2 The basis for using IAD therapy is the observation that tumor cells that survive androgen withdrawal will undergo repeated cycles of apoptosis and expansion (growth) when exposed to intermittent episodes of androgen withdrawal and replacement, respectively. 3 This process will subsequently prolong the time to AI and lead to improved patients' survival. Indeed, preliminary data suggest that the androgen-dependent (AD) phase of CaP can be maintained during IAD therapy with no signi®cant risks and no compromise to quality of life. 1, 2 Eventually, however, CaP will resume growth despite androgen withdrawal therapy, whether intermittent or continuous, resulting in tumor progression and development of HRPC. Akakura et al measured the effects of IAD on the stem cell composition in a Shionogi carcinoma animal model using in vivo limiting dilution assays. They found that the proportion of AI cells in the stem cell population increased from 0.8% prior to androgen ablation to 47% after four cycles of IAD. 4 It was further concluded that the conversion of the tumor phenotype to AI occurred when one-third to one-half of the total stem cell compartment was populated by AI stem cells. 4 It thus appears that androgen deprivation is a contributing factor pressuring the selection and outgrowth of a clonal population of more aggressive cells over time.
There are several possible theories to explain the AI progression of tumors into HRPC phenotypes: (i) androgen resistance may result from activation of intracellular adaptive mechanisms in tumor cells deprived of androgen. This explanation is supported by the in vivo studies of Akakura et al; 3 (ii) alternatively, clonal expansion of AI cells found in the tumor at a very low frequency prior to hormonal ablation that selectively outgrow while the AD cells suffer an apoptotic crisis or undergo a dormant period induced by androgen deprivation. 4 Reactivation of an androgen receptor pathway by a ligand-independent mechanism was also recently proposed. 5 At the present time the exact mechanism leading to AI progression remains unclear and very little experimental evidence is available to support either of these concepts. With the current availability of improved tumor models this fundamental question can now be tested in vivo.
Pulsed androgen deprivation
Our overall objective is to develop a more effective androgen deprivation-based treatment capable of delaying the process of CaP tumor progression from AD to AI stage and from locally advanced to widely metastatic disease using our newly developed CL1-GFP tumor model. We have established an AI CaP line, designated CL1, via an in-vitro androgen deprivation treatment of an AD CaP line, LNCaP. 6 In contrast to the slow growing, AD, and poorly tumorogenic phenotype of parental LNCaP cells, this LNCaP derived AI variant was fastgrowing, and had acquired signi®cant resistant to radiation and anti-cancer cytotoxic agents. Moreover, CL1 proved to be highly tumorigenic, exhibiting invasive and metastatic characteristics in intact or castrated mice, even in the absence of growth supplements (for example Matrigel). When transfected with the green¯uorescence protein (GFP) gene (CL1-GFP) and transplanted orthotopically into the prostate, a primary tumor developed within 2 weeks. Detectable metastasis in bone, lymph nodes, lung, liver, spleen, kidney and brain occurs within 4 ± 5 weeks.
When compared to parental AD LNCaP cells, overexpression of autocrine growth factors and angiogenic factors transcripts, such as mRNAs of basic ®broblast growth factor (b-FGF), interleukin-6 (IL-6), IL-8, vascular endothelial cell growth factor (VEGF), transforming growth factor-b1 (TGF-b1), TGF-b2 and epidermal growth factor receptor (EGF-R) was detected in CL1 cells and CL1 tumor. Loss of E-cadherin, p53 and PTEN and augmented expression of BCL-2 mRNA were also observed in CL1 tumors. Despite the long-term culture of CL1 cells in androgen-free culture conditions, a low-level expression of androgen receptor (AR)-mRNA was detected in both CL1 cell line and tumors while PSA was not detectable. These ®ndings indicate that androgen deprivation in tissue culture can lead to the selective outgrowth of aggressive AI CaP variants that operate by an alternative growth-signaling pathway independent of androgen. The biological function of AR, which was detected in CL1 cells, remains unknown. Thus, we propose to develop new therapeutic strategies to suppress the outgrowth of AI variants that carry aggressive cellular and molecular properties as characterized in CL1 line.
In most clinical IAD trials the decision to stop androgen withdrawal therapy is based on monitoring PSA concentration, waiting for its drop to nadir within 8 ± 9 months of treatment start. Thereafter, treatment is reintroduced if and when PSA levels are increased to 20 ng/ml. 2 We used our LNCaP AD cell culture system to correlate between the progression of AI cells in vitro during androgen withdrawal and their expression of PSA. We observed that non-reversible AI variants were established and expanded (CL1) in the fourth week of androgen-deprivation while PSA mRNA expression was still clearly seen, and they continued to proliferate in the ®fth week of androgen deprivation. However, PSA mRNA expression was barely detectable thereafter, namely on the ®fth to sixth weeks. Thus, in our in vitro system AI burst occurred signi®cantly earlier than PSA nadir, implying that PSA levels may not serve as an indicator (`warning sign') for AI progression in the tumor.
Replacement of androgen into an LNCaP-derived CL1 culture that was deprived of androgen for 6 weeks did not lead to reversal to AD phenotype, indicating that selection of a pure AI population was accomplished after the 6 week treatment. Therefore, we tested an alternative IAD protocol in vitro in which we applied shorter intervals of androgen withdrawal. Our results demonstrate that LNCaP cells treated with IAD using weekly intervals (one week of ablation and one week of replacement) maintained the slow-growing characteristics of non-treated parental LNCaP cells and did not support the expansion of rapidly dividing cells. Continuous androgen deprivation treatment, however, resulted in the selection of the fast growing cell population.
We sought to determine whether LNCaP cells can suppress the growth of co-cultured AI CL1-GFP cells. The growth of CL1-GFP cells was suppressed when cocultured with LNCaP in the presence of androgen whereas in the absence of androgen, CL1-GFP triple their amount in less than 5 days. This suppressive effect was no longer detectable when the initial AI (CL1-GFP)/ AD (LNCaP) ratio was above 1 : 5. In addition, we further found that the proliferation of CL1 cells could be suppressed by the condition media derived from LNCaP cells in a dose-dependent manner, whereas R11 (renal cancer cell line, tumorogenic in mice) -conditioned medium or condition medium derived from CL1 cells had no such effect. This inhibitory effect of LNCaP-condition medium points to the presence of soluble growth-inhibitory factors secreted by LNCaP cells.
We believe that IAD with shorter intervals of androgen withdrawal, which we have designated pulsed androgen deprivation (PAD) will destroy AD cells more gradually and conserve their AI-inhibitory potential for longer periods, resulting in an overall prolongation of time to progression to hormone resistance. Based upon our preclinical ®ndings, we have proposed a clinical trial of`on ± off' PAD ( Figure 1) . This trial will be a prospective study evaluating the toxicity and ef®cacy of our modi®ed intermittent androgen deprivation schedule for patients requiring long-term androgen withdrawal therapy. Candidates for this study will include patients with advanced or metastatic prostate adenocarcinoma who are not considered candidates for local therapy (surgery or radiation), whose primary cancer is in place, and for whom hormonal treatment would be their primary therapy. Treatment will consist of`on ± off' cycles of medical castration using androgen suppression therapy with LHRH agonists. Treatment cycles will be continued until androgen independence is noted, de®ned as three consecutive rises in serum PSA above 4.0 ng/ml in the presence of suppressed testosterone levels. The study's hypothesis is that during the`off therapy' phase, this approach will offer improved quality of life with reduced toxicity and cost and that the improved therapeutic schedule will delay time to androgen independence.
Patients will be followed during the study using parameters to evaluate evidence of disease progression and to calculate survival data. These parameters will include serum PSA, digital rectal exam, transrectal ultrasound of the prostate to follow prostate and tumor volumes, bone scan to follow progression of bony metastases, RT-PCR for PSA, prostate biopsy to follow molecular markers including estimates of apoptosis and cellular proliferation, as well as hip and spine bone mineral density studies to estimate the effect of pulsed androgen therapy on loss of bone density.
Conclusions
Based on our preliminary studies, we have adopted the following working hypothesis to explain progression to androgen independence:
1. AI clones pre-exist in the untreated tumor and under androgen deprivation pressure undergo clonal expansion.
2. A dynamic`cross-talk' between AD and AI cells does exist in the original tumor, with the AD tumor cells capable of inducing growth suppression of AI cells. Disruption of the balance between these two populations results in aggressive growth and metastasis. 3. The presence of active AD cells in the tumor is a prerequisite to delay progression to AI stage. 4. Reducing PSA to undetectable levels disrupts the AD/AI balance and enhances the process of tumor progression.
Given our observations in the CL1-GFP model originally derived from LNCaP cells, that AI cells can be suppressed by either co-culturing with actively growing parental AD cells or in the presence of their condition media, and the fact that AI cells expansion/growth appears to precede the PSA nadir, we here propose to test shorter intervals of androgen deprivation and start androgen replacement early in the course and well before PSA reaches its nadir. Combining in vitro/in vivo experiments using AI CL1-GFP cells mixed with their parental AD LNCaP cells will help to de®ne the intratumoral dynamics and in-situ molecular lesions leading to clonal expansion and AI tumor progression. We aim to identify both cellular and molecular mechanisms involved in PAD-mediated delay in AI progression and modify the cycles and schedules of therapy based on these ®ndings. With our newly developed and well-characterized CL1-GFP model and the availability of its parental AD cells and tumor model we are well positioned to test these concepts in vitro and in vivo.
